Progranulin Intervention in Inflammatory Bowel Diseases

颗粒体蛋白前体干预炎症性肠病

基本信息

  • 批准号:
    8708276
  • 负责人:
  • 金额:
    $ 21.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-15 至 2015-08-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ulcerative colitis and Crohn's disease are chronic, relapsing inflammatory disorders of the gastrointestinal tract, collectively known as Inflammatory Bowel Disease (IBD). The cause of IBD, which in the U.S. affects an estimated 1.4 million individuals, remains largely unknown. Pro-inflammatory cytokines are believed to play important roles in the pathogenesis of IBD. Among these cytokines, tumor necrosis factor (TNF) has received the greatest attention because of its position at the apex of the inflammatory and immune-regulatory cascades. TNF inhibitors, such as Remicade and Enbrel, have been accepted as an effective approach to treating various kinds of inflammatory diseases, including Crohn's disease and ulcerative colitis. However, their side effects and high cost prompt investigations into new, alternative treatment modalities. One such alternative is a long- known anti-inflammatory growth factor, progranulin (PGRN), which was only recently discovered to be a novel ligand of TNF receptors (TNFR) in our global genetic screen. We recently reported that PGRN antagonizes TNF activity and significantly attenuates or ameliorates experimentally induced inflammatory arthritis in mice. More importantly, Atsttrin, an engineered protein composed of three PGRN fragments, exhibited highly potent anti-inflammatory activity, which surpassed PGRN itself, in vivo. Using PGRN deficient mice, we demonstrated in our preliminary studies that the deletion of the PGRN gene renders B6 mice more susceptible to Dextran Sulfate Sodium (DSS) induction and to developing more severe colitis. In addition, PGRN antagonizes TNF¿- mediated down-regulation of Treg suppressive function and Foxp3 expression; in vivo treatment with PGRN selectively stimulates IL-10 production in Treg cells and PGRN-stimulated Treg suppressive function is largely lost if IL-10 signaling is blocked. These studies have led to the central hypothesis that PGRN exerts its protective effects through its interaction with TNFR and the stimulation of IL-10 producing Treg cells in the course of inflammatory bowel disease. This hypothesis will be tested in three Specific Aims: (1) Do PGRN-mediated signaling and molecular events depend on PGRN's interaction with TNF/TNFR in Tregs and in inflammatory bowel disease? (2) Is IL-10 a critical mediator of PGRN action in the pathogenesis of inflammatory bowel disease? (3) Can recombinant PGRN, especially its derived Atsttrin, be directly applied to treat inflammatory bowel disease? Successful completion of the proposed research will not only benefit our understanding of the pathogenesis of IBD, but also lead to the development of new anti-TNF/TNFR therapeutic interventions for various kinds of TNF-related diseases, including IBD. .
描述(由申请人提供):溃疡性结肠炎和克罗恩病是胃肠道的慢性复发性炎症性疾病,统称为炎症性肠病(IBD)。IBD的病因在美国影响了大约140万人,但在很大程度上仍然未知。促炎细胞因子在IBD的发病机制中起重要作用。在这些细胞因子中,肿瘤坏死因子(TNF)由于其位于炎症和免疫调节级联反应的顶点而受到最大的关注。TNF抑制剂,如Remicade和Enbrel,已被接受为治疗各种炎症性疾病,包括克罗恩病和溃疡性结肠炎的有效方法。然而,它们的副作用和高成本促使人们研究新的替代治疗方式。一种这样的替代物是长期已知的抗炎生长因子,颗粒蛋白前体(PGRN),其最近才在我们的全球遗传筛选中被发现是TNF受体(TNFR)的新型配体。我们最近报道,PGRN拮抗TNF活性,并显着减轻或改善实验诱导的小鼠炎症性关节炎。更重要的是,Atsttrin,一种由三个PGRN片段组成的工程蛋白,在体内表现出高度有效的抗炎活性,超过了PGRN本身。使用PGRN缺陷小鼠,我们在我们的初步研究中证明,PGRN基因的缺失使B6小鼠更容易受到葡聚糖硫酸钠(DSS)诱导,并发展成更严重的结肠炎。此外,PGRN拮抗TNF-α介导的Treg抑制功能和Foxp 3表达的下调;用PGRN进行的体内治疗选择性地刺激Treg细胞中的IL-10产生,并且如果IL-10信号传导被阻断,则PGRN刺激的Treg抑制功能在很大程度上丧失。这些研究导致了中心假设,即PGRN通过其与TNFR的相互作用和在炎性肠病过程中刺激产生IL-10的Treg细胞来发挥其保护作用。这一假设将在三个特定的目的进行测试:(1)PGRN介导的信号传导和分子事件是否取决于PGRN与TNF/TNFR在THP和炎症性肠病中的相互作用?(2)IL-10是炎症性肠病发病机制中PGRN作用的关键介质吗?(3)重组PGRN,特别是其衍生的Atsttrin,能否直接用于治疗炎症性肠病?该研究的成功完成不仅有助于我们对IBD发病机制的理解,而且还有助于开发新的抗TNF/TNFR治疗干预措施,用于各种TNF相关疾病,包括IBD。.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chuanju Liu其他文献

Chuanju Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chuanju Liu', 18)}}的其他基金

Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes
靶向 TNF 受体抑制炎症并促进 1 型糖尿病的骨再生
  • 批准号:
    10915157
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
The immunological mechanism of PGRNs anti-inflammatory effect
PGRNs抗炎作用的免疫学机制
  • 批准号:
    10912299
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
The Role of Sodium Channel Nav1.7 in Osteoarthritis - Resubmission - 1
钠通道 Nav1.7 在骨关节炎中的作用 - 重新提交 - 1
  • 批准号:
    10390155
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
A new mouse model to study GBA1 mutation-associated diseases with multiple organs involvement
研究GBA1突变相关多器官疾病的新小鼠模型
  • 批准号:
    10651885
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
A new mouse model to study GBA1 mutation-associated diseases with multiple organs involvement
研究GBA1突变相关多器官疾病的新小鼠模型
  • 批准号:
    10508985
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes - Resubmission - 1
靶向 TNF 受体抑制 1 型糖尿病炎症并促进骨再生 - 重新提交 - 1
  • 批准号:
    10453563
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes - Resubmission - 1
靶向 TNF 受体抑制 1 型糖尿病炎症并促进骨再生 - 重新提交 - 1
  • 批准号:
    10218061
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:
Progranulin: A Novel Gene in Gaucher Diseases
颗粒体蛋白前体:戈谢病的一个新基因
  • 批准号:
    10251862
  • 财政年份:
    2017
  • 资助金额:
    $ 21.19万
  • 项目类别:
Progranulin: A Novel Gene in Gaucher Diseases
颗粒体蛋白前体:戈谢病的一个新基因
  • 批准号:
    10011889
  • 财政年份:
    2017
  • 资助金额:
    $ 21.19万
  • 项目类别:
The Role of PGRN Growth Factor in Osteoarthritis
PGRN 生长因子在骨关节炎中的作用
  • 批准号:
    8698896
  • 财政年份:
    2013
  • 资助金额:
    $ 21.19万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了